King's College London

Research portal

Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation

Research output: Contribution to journalArticle

Standard

Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas : A nationally coordinated approach to delivery and prospective evaluation. / Morris, Katrina A.; Golding, John F.; Axon, Patrick R.; Afridi, Shazia; Blesing, Claire; Ferner, Rosalie E.; Halliday, Dorothy; Jena, Raj; Pretorius, Pieter M.; Gareth Evans, D.; McCabe, Martin G.; Parry, Allyson.

In: Neuro-Oncology Practice, Vol. 3, No. 4, 01.12.2016, p. 281-289.

Research output: Contribution to journalArticle

Harvard

Morris, KA, Golding, JF, Axon, PR, Afridi, S, Blesing, C, Ferner, RE, Halliday, D, Jena, R, Pretorius, PM, Gareth Evans, D, McCabe, MG & Parry, A 2016, 'Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation', Neuro-Oncology Practice, vol. 3, no. 4, pp. 281-289. https://doi.org/10.1093/nop/npv065

APA

Morris, K. A., Golding, J. F., Axon, P. R., Afridi, S., Blesing, C., Ferner, R. E., Halliday, D., Jena, R., Pretorius, P. M., Gareth Evans, D., McCabe, M. G., & Parry, A. (2016). Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice, 3(4), 281-289. https://doi.org/10.1093/nop/npv065

Vancouver

Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE et al. Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice. 2016 Dec 1;3(4):281-289. https://doi.org/10.1093/nop/npv065

Author

Morris, Katrina A. ; Golding, John F. ; Axon, Patrick R. ; Afridi, Shazia ; Blesing, Claire ; Ferner, Rosalie E. ; Halliday, Dorothy ; Jena, Raj ; Pretorius, Pieter M. ; Gareth Evans, D. ; McCabe, Martin G. ; Parry, Allyson. / Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas : A nationally coordinated approach to delivery and prospective evaluation. In: Neuro-Oncology Practice. 2016 ; Vol. 3, No. 4. pp. 281-289.

Bibtex Download

@article{0d1bfdcdafcf41af9cc342cffab92ebe,
title = "Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation",
abstract = "Background. NF2 patients develop multiple nervous system tumors including bilateral vestibular schwannomas (VS). The tumors and their surgical treatment are associated with deafness, neurological disability, and mortality. Medical treatment with bevacizumab has been reported to reduce VS growth and to improve hearing. In addition to evaluating these effects, this study also aimed to determine other important consequences of treatment including patient-reported quality of life and the impact of treatment on surgical VS rates. Methods. Patients treated with bevacizumab underwent serial prospective MRI, audiology, clinical, CTCAE-4.0 adverse events, and NFTI-QOL quality-of-life assessments. Tumor volumetrics were classified according to the REiNs criteria and annual VS surgical rates reviewed. Results. Sixty-one patients (59% male), median age 25 years (range, 10-57), were reviewed. Median follow-up was 23 months (range, 3-53). Partial volumetric tumor response (all tumors) was seen in 39% and 51% had stabilization of previously growing tumors. Age and pretreatment growth rate were predictors of response. Hearing was maintained or improved in 86% of assessable patients. Mean NFTI-QOL scores improved from 12.0 to 10.7 (P,.05). Hypertension was observed in 30% and proteinuria in 16%. Twelve treatment breaks occurred due to adverse events. The rates of VS surgery decreased after the introduction of bevacizumab. Conclusion. Treatment with bevacizumab in this large, UK-wide cohort decreased VS growth rates and improved hearing and quality of life. The potential risk of surgical iatrogenic damage was also reduced due to an associated reduction in VS surgical rates. Ongoing follow-up of this cohort will determine the long-term benefits and risks of bevacizumab treatment.",
keywords = "Bevacizumab, Neurofibromatosis type 2, Schwannoma, Vestibular schwannoma",
author = "Morris, {Katrina A.} and Golding, {John F.} and Axon, {Patrick R.} and Shazia Afridi and Claire Blesing and Ferner, {Rosalie E.} and Dorothy Halliday and Raj Jena and Pretorius, {Pieter M.} and {Gareth Evans}, D. and McCabe, {Martin G.} and Allyson Parry",
year = "2016",
month = dec,
day = "1",
doi = "10.1093/nop/npv065",
language = "English",
volume = "3",
pages = "281--289",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "4",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas

T2 - A nationally coordinated approach to delivery and prospective evaluation

AU - Morris, Katrina A.

AU - Golding, John F.

AU - Axon, Patrick R.

AU - Afridi, Shazia

AU - Blesing, Claire

AU - Ferner, Rosalie E.

AU - Halliday, Dorothy

AU - Jena, Raj

AU - Pretorius, Pieter M.

AU - Gareth Evans, D.

AU - McCabe, Martin G.

AU - Parry, Allyson

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background. NF2 patients develop multiple nervous system tumors including bilateral vestibular schwannomas (VS). The tumors and their surgical treatment are associated with deafness, neurological disability, and mortality. Medical treatment with bevacizumab has been reported to reduce VS growth and to improve hearing. In addition to evaluating these effects, this study also aimed to determine other important consequences of treatment including patient-reported quality of life and the impact of treatment on surgical VS rates. Methods. Patients treated with bevacizumab underwent serial prospective MRI, audiology, clinical, CTCAE-4.0 adverse events, and NFTI-QOL quality-of-life assessments. Tumor volumetrics were classified according to the REiNs criteria and annual VS surgical rates reviewed. Results. Sixty-one patients (59% male), median age 25 years (range, 10-57), were reviewed. Median follow-up was 23 months (range, 3-53). Partial volumetric tumor response (all tumors) was seen in 39% and 51% had stabilization of previously growing tumors. Age and pretreatment growth rate were predictors of response. Hearing was maintained or improved in 86% of assessable patients. Mean NFTI-QOL scores improved from 12.0 to 10.7 (P,.05). Hypertension was observed in 30% and proteinuria in 16%. Twelve treatment breaks occurred due to adverse events. The rates of VS surgery decreased after the introduction of bevacizumab. Conclusion. Treatment with bevacizumab in this large, UK-wide cohort decreased VS growth rates and improved hearing and quality of life. The potential risk of surgical iatrogenic damage was also reduced due to an associated reduction in VS surgical rates. Ongoing follow-up of this cohort will determine the long-term benefits and risks of bevacizumab treatment.

AB - Background. NF2 patients develop multiple nervous system tumors including bilateral vestibular schwannomas (VS). The tumors and their surgical treatment are associated with deafness, neurological disability, and mortality. Medical treatment with bevacizumab has been reported to reduce VS growth and to improve hearing. In addition to evaluating these effects, this study also aimed to determine other important consequences of treatment including patient-reported quality of life and the impact of treatment on surgical VS rates. Methods. Patients treated with bevacizumab underwent serial prospective MRI, audiology, clinical, CTCAE-4.0 adverse events, and NFTI-QOL quality-of-life assessments. Tumor volumetrics were classified according to the REiNs criteria and annual VS surgical rates reviewed. Results. Sixty-one patients (59% male), median age 25 years (range, 10-57), were reviewed. Median follow-up was 23 months (range, 3-53). Partial volumetric tumor response (all tumors) was seen in 39% and 51% had stabilization of previously growing tumors. Age and pretreatment growth rate were predictors of response. Hearing was maintained or improved in 86% of assessable patients. Mean NFTI-QOL scores improved from 12.0 to 10.7 (P,.05). Hypertension was observed in 30% and proteinuria in 16%. Twelve treatment breaks occurred due to adverse events. The rates of VS surgery decreased after the introduction of bevacizumab. Conclusion. Treatment with bevacizumab in this large, UK-wide cohort decreased VS growth rates and improved hearing and quality of life. The potential risk of surgical iatrogenic damage was also reduced due to an associated reduction in VS surgical rates. Ongoing follow-up of this cohort will determine the long-term benefits and risks of bevacizumab treatment.

KW - Bevacizumab

KW - Neurofibromatosis type 2

KW - Schwannoma

KW - Vestibular schwannoma

UR - http://www.scopus.com/inward/record.url?scp=84989871139&partnerID=8YFLogxK

U2 - 10.1093/nop/npv065

DO - 10.1093/nop/npv065

M3 - Article

AN - SCOPUS:84989871139

VL - 3

SP - 281

EP - 289

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 4

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454